Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...
EuropaWire19h
Sanofi Accelerates Chlamydia Prevention with Fast Tracked mRNA Vaccine
Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to addr ...
Sanofi: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer ...
Press Release: Availability of the Q1 2025 Aide mémoire
Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) ...
Fintel on MSN5d
Goldman Sachs Initiates Coverage of Sanofi - Depositary Receipt () (SNY) with Neutral Recommendation
Fintel reports that on March 21, 2025, Goldman Sachs initiated coverage of Sanofi - Depositary Receipt () (NasdaqGS:SNY) with ...
BioPharma Dive6d
Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease
The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...
BioSpace17d
FDA Action Alert: GSK, Alnylam, Sanofi and More
Alnylam’s bid for label expansion is backed by the HELIOS-B study, data from which were published in the New England Journal of Medicine in August 2024 ... Alnylam’s second showing on this list is for ...
STAT22d
Pharmalittle: We’re reading about lower Wegovy prices, a dispute over Merck’s Keytruda, and more
a professor of law and medicine at McGill University who specializes in intellectual property issues, tells STAT. As he sees it, the pharmaceutical industry would have a lot to lose should the ...
Daily Maverick22d
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...
Bloomberg L.P.22d
Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...
Reuters23d
South African watchdog probes Novo Nordisk and Sanofi over insulin
March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...